Agios Pharmaceuticals | Frais De Vente Et D'Administration



Selling And Administration Expenses Changement Date
AbbVie USD 3.29B 562M 2025-03
Agios Pharmaceuticals USD 51.7M 13.16M 2024-12
Alnylam Pharmaceuticals USD 295.34M 74.35M 2024-12
Amgen USD 1.88B 253M 2024-12
Arrowhead Research USD 30.2M 1.91M 2024-12
Astellas Pharma JPY 211.32B 13.99B 2025-03
AstraZeneca USD 3.59B 1.96B 2025-03
Bayer EUR 4.34B 610M 2024-12
Biogen USD 677.3M 99.6M 2024-12
BioMarin Pharmaceutical USD 256.77M 46.81M 2024-12
Bristol-Myers Squibb USD 1.58B 521M 2025-03
Daiichi Sankyo JPY 208.21B 22.58B 2025-03
Eli Lilly USD 2.36B 62.3M 2025-03
Exelixis USD 134.33M 22.53M 2025-01
Gilead Sciences USD 1.26B 603M 2025-03
GlaxoSmithKline GBP 2.06B 603M 2025-03
Incyte USD 325.69M 1.02M 2025-03
Ionis Pharmaceuticals USD 76M 12.08M 2025-03
Merck USD 2.53B 319M 2025-03
Moderna USD 212M 139M 2025-03
Novartis USD 3.5B 368M 2024-12
Novartis USD 3.5B 368M 2024-12
Pfizer USD 3.01B 1.27B 2025-03
Regeneron Pharmaceuticals USD 633M 159.2M 2025-03
Roche Holding CHF 3.61B 381M 2024-12
Sarepta Therapeutics USD 163.87M 35.67M 2024-12
Vertex Pharmaceuticals USD 377.6M 5.8M 2024-12



Agios Pharmaceuticals Frais De Vente Et D'Administration - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2025.